INTERNATIONAL COLLABORATIVE EXERCISES (ICE)

INTERNATIONAL COLLABORATIVE

EXERCISES (ICE)

ICE

20

20

/2

Summary Report

ICE Round 2020/2

BIOLOGICAL SPECIMENS

International Collaborative Exercises (ICE)Summary report 2020/2- Biological Specimens

Copyright © 2021 UNODC

Page 1 of 62

ICE 2020/2-BS

Final summary report for ICE 2020/2 Biological Specimens Test Group

Original language: English

© United Nations, August 2021. All rights reserved, worldwide.

The designations employed and the presentation of material in this publication do not imply the expression of

any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any

country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries.

This publication has not been formally edited.



Page 2 of 62

ICE 2020/2-BS

Acknowledgements

The Laboratory and Scientific Service (LSS) of the UNODC, headed by Dr. Justice Tettey, wishes to express its appreciation and thanks to all laboratories for participating in the International Collaborative Exercises (ICE) round 2020/2. The valuable comments and contribution from the following members of the International Panel of Forensic Experts are gratefully acknowledged: Mr. Benoit Archambault, Health Canada, Canada Mr. Elvio Dias Botelho, Brazilian Federal Police, Brazil Prof. Heesun Chung, Sungkyunkwan University, Republic of Korea Prof. Niamh Nic Daéid, University of Dundee, Scotland, UK Mr. Scott Oulton, Drug Enforcement Administration, USA Ms. Catherine Quinn, Victoria Police, Australia Prof. Franco Tagliaro, University of Verona, Italy Dr. Angeline Tiong Whei Yap, Health Sciences Authority, Singapore In addition, LSS would like to acknowledge the valuable contribution of the Chemical Metrology Laboratory of the Health Sciences Authority, Singapore, for the provision of specific software used for the quantitative statistical calculations in the ICE programme. The ICE is coordinated by Ms. Yen Ling Wong, Scientific Affairs Officer, a staff member of LSS. The assistance and the contributions of the following LSS staff members are gratefully acknowledged. Dr. Conor Crean, Scientific Affairs Officer Mr. Joao Rodrigues, Scientific Affairs Officer Ms. Romana Luger, Research Assistant Dr. Gerd Krapf, Laboratory Technician Mr. Michael Bell, Laboratory Technician Ms. Mikaela Edwards, Laboratory Team Assistant For additional information or comments, please contact: Ms. Yen Ling Wong ICE Coordinator Scientific Affairs Officer Laboratory and Scientific Service UNODC, Vienna International Centre Wagramer Strasse 5, P.O. Box 500 A-1400, Vienna, AUSTRIA Email: [email protected]



Page 3 of 62

ICE 2020/2-BS

Contents

1. Codes and Abbreviations ..............................................................................................................................4

2. Test samples information .............................................................................................................................5

3. Introduction ..................................................................................................................................................6

4. Comments from the International Panel of Forensic Experts ......................................................................7

5. New Psychoactive Substances (NPS) reported .............................................................................................9

6. Summary of responses for Test Sample-1 ................................................................................................. 11




10. ANNEX 1: Participants’ results for Test Sample-1 ..................................................................................... 25






Page 4 of 62

ICE 2020/2-BS

1. Codes and Abbreviations (+) “positive” Indicates that the analyte is identified; for presumptive tests (e.g. colour reactions), indicates

that a positive reaction was obtained.

(-) “negative” Indicates that the analyte is not identified.

(ANP) Analysis not performed.

Tech Code Name

100 Agglutination techniques

110 Enzyme immunoassay techniques

120 Fluorescence polarization immunoassay

130 Radioimmunoassay

140 Colorimetric reactions

141 Marquis test

142 Cobalt thiocyanate test

150 Thin layer chromatography (TLC)

160 High/ultra high performance liquid chromatography with ultraviolet-visible spectroscopy (HPLC/UPLC)

161 High/ultra high performance liquid chromatography with diode array detection (HPLC-DAD or UPLC-DAD)*

170 Gas chromatography with nitrogen-phosphorous detection (GC-NPD)

171 Gas chromatography with flame ionization detection (GC-FID)

172 Gas chromatography with electron capture detection (GC-ECD)

180 Gas chromatography with mass spectrometry (GC-MS)

190 Fourier transform infrared spectrometry (FTIR)

200 Spectrophotometry (visible, UV)

210 Others

211 Nuclear magnetic resonance spectroscopy (NMR)

220 Microcrystal test

230 Liquid chromatography with mass spectrometry (LC-MS)

231 Liquid chromatography with tandem mass spectrometry (LC-MS/MS)

*similar to 160



Page 5 of 62

ICE 2020/2-BS

2. Test samples information The following four (4) test samples for the Biological Specimens test group were prepared by a private company under subcontract with the Laboratory and Scientific Service, UNODC: Test Sample-1 (BS-1) To prepare BS-1, urine was spiked with an aqueous solution of morphine sulphate. The spiked urine was dispensed in 25 mL aliquots and lyophilised. Test Sample-2 (BS-2) To prepare BS-2, urine was spiked with an ethanolic solution of buprenorphine hydrochloride and a methanolic solution of norbuprenorphine to achieve final concentrations of 920 ng base/mL for both analytes. The spiked urine was dispensed in 25 mL aliquots and lyophilised. Test Sample-3 (BS-3) To prepare BS-3, urine was spiked with a methanolic solution of nordazepam to achieve a final concentration of 460 ng base/mL. The spiked urine was dispensed in 25 mL aliquots and lyophilised. Test Sample-4 (BS-4) To prepare BS-4, urine was spiked with a methanolic solution of MDMA hydrochloride to achieve a final concentration of 860 ng base/mL. The spiked urine was dispensed in 25 mL aliquots and lyophilised. All test samples were prepared from urine free of all major groups of abused drugs. Metabolites of caffeine may be present. No preservatives were added to the urine samples. All analytes spiked into the test samples were commercially sourced reference standards.



Page 6 of 62

ICE 2020/2-BS

3. Introduction An important element of the UNODC International Quality Assurance Programme (IQAP) is the

implementation of the International Collaborative Exercises (ICE). The exercises allow laboratories, from both

developing and developed countries to continuously monitor their performance in drug testing on a truly

global scale. This report provides information on analytical results of laboratories participating in the Biological

Specimens (BS) test group. In order to maintain confidentiality, the participating laboratories have been

assigned random “Round Codes”, which change every round.

The analytical results returned by laboratories participating in ICE are evaluated by UNODC and a confidential

report is provided to each laboratory on its own performance. The overall analytical results are reviewed by

the UNODC’s International Panel of Forensic Experts which oversees the implementation of these exercises,

and offers guidance and support in addressing relevant quality issues. The exercises provide an overview of

the performance and capacity of participating laboratories and enable UNODC to tailor technical support in

the laboratory sector for greatest impact.

The ICE programme is a UNODC mandated activity and is implemented through regular budget funds and

through the UNODC Global Scientific and Forensic Programme – Support Project (GLOU54), which

operationalizes the forensic aspects of the UNODC Thematic Programme on Research, Trend Analysis and

Forensics". Figure 1 shows the growth of the programme in the last 10 years for both the Seized Materials (SM)

and the Biological Specimens (BS) test groups.

Note: Reduced participation rate in rounds 2020/1 and 2020/2 resulted from the challenges arising from the

COVID-19 pandemic.

Figure 1. Growth of the ICE programme (as of 5 August 2021)

100 102

116

129 132 131

151159

179173

184 185

204 204 204195

222 226

208

179

3747

5462 58 62

72 7486 90

95 92 96 97 9388

101106

96

84

0

50

100

150

200

250

No

. of

lab

ora

tori

es

ICE round

SM BS



Page 7 of 62

ICE 2020/2-BS

4. Comments from the International Panel of Forensic Experts

4.1 Participation of Laboratories in ICE round 2020/2

In the 2020/2 round of the ICE programme, results were submitted within both the Seized Materials (SM)

and Biological Specimens (BS) test groups by 225 laboratories in 66 countries. Within the BS test group,

results were submitted by 84 participating laboratories from 39 countries and within the SM test group,

there were 179 laboratories from 57 countries. The reduced participation rate of this round and the

previous round is mainly due to shipping restrictions to a number of countries experiencing on-going

COVID-19 pandemic.

4.2 Qualitative Analysis

The analytical techniques most commonly used for screening of test samples in the BS test group were

immunoassays (61% of participants). GC-MS (79% of participants) was the most commonly used technique

for identification/confirmation of the components in the test samples, followed by LC-MS/MS (48% of

participants). The results for the qualitative identification of the sample components in the BS test group,

the number of false positive/negative results and the analyses not performed are shown in Table 1.

Table 1. Performance of participants in the 2020/2 round of ICE.

Test sample BS-1*

(Morphine)

BS-2 BS-3 BS-4

(Buprenorphine) (Norbuprenorphine) (Nordazepam) (MDMA)

Correct identification by participants

61.9% 78.6% 56.0%

90.5% 90.5% At least 1 component: 79.8%

Number of false positives

2 3 6 7

Number of false negatives

20 6 3 7

Number of analyses not performed

12 11 5 1

Overall, only a total of 45% of participants were able to identify all 4 test samples correctly. This was mainly

due to the low concentration of morphine (69 ng/mL) in test sample BS-1* which was below cut-offs set by

laboratories, resulting in 20 participants obtaining false negatives for this test sample. With regards to false

positive results, there were a total of 18 false positive results, which is a slight decrease in number

compared to the previous round. Nonetheless, laboratories reporting false positive or false negative results

should investigate the reasons for this and corrective actions should be taken as soon as possible in order

to continuously improve performance. A number of participants did not perform analysis on test samples

BS-1 and BS-2 containing morphine and buprenorphine/norbuprenorphine, respectively. ICE participants

are reminded that test samples can contain any of the substances in the ICE menu and as such if methods

are available, all substances should be considered.

Note: *The concentration of morphine in test sample 2020/1/BS-1 was found to differ considerably from the stated amount

prepared by a private contracted company. Hence for this test sample, only qualitative results were evaluated.



Page 8 of 62

ICE 2020/2-BS

4.3 Quantitative Analysis

The test samples in the BS group for the 2020/2 round of ICE contained a total of four components for

quantification and 38 (45%) laboratories performed quantification. Of these laboratories, it is encouraging

to note that 87% of laboratories quantified at least two components and 45% performed quantification of

all four components. LC-MS/MS, used by 53% of participants, was the most commonly used technique for

quantitation, followed by GC-MS, which was used by 50% of participants. z-Scores obtained by participants

in quantification are shown in Table 2 below (percentage + no. of labs indicated).

Table 2. Quantitative performance of participants in the 2020/2 round of ICE.

In general, the performance of laboratories improved with more laboratories achieving acceptable z-scores.

According to the recommendations in ISO 13528:2015, an unacceptable z-score is considered to give an

action signal and a questionable z-score is considered to give a warning signal. A single action signal or

warning signal in two successive rounds shall be taken that an anomaly has occurred that requires

investigation. Participants with z-scores outside acceptable limits should review their quantification

procedures as soon as possible.

The following 2 laboratories obtained a single action signal or warning signal in the two successive rounds

of 2020/1 and 2020/2 and shall take this as anomaly, which requires further investigation: U4DAAJ and

VUASIY.

One laboratory, U4DAAJ, that obtained a single action or warning signal in ICE rounds 2019/2 and 2020/1,

was also found to obtained action or warning signals in this round.

Laboratories that need to perform quantitation routinely are encouraged to participate regularly in

external proficiency testing or collaborative exercises such as the ICE programme. This will enable

laboratories to assess the quality of their quantitative methods through the z-score values obtained.

Laboratories reporting false positive or false negative results should investigate the root causes and

corrective actions taken promptly in order to continuously improve performance. Participation in the ICE

programme also helps in monitoring the effect of corrective actions.

z-score

Test sample

BS-2 (920 ng/mL

Buprenorphine)

BS-2 (920 ng/mL

Norbuprenorphine)

BS-3 (460 ng/mL

Nordazepam)

BS-4 (860 ng/mL MDMA)

|z| ≤ 2.00, acceptable

89.3% (25) 95.0% (19) 88.2% (30) 94.1% (32)

2.00 < |z| < 3.00, questionable

3.6% (1) 0.0% (0) 2.9% (1) 5.9% (2)

|z| ≥ 3.00, unacceptable

7.1% (2) 5.0% (1) 8.9% (3) 0.0% (0)



Page 9 of 62

ICE 2020/2-BS

5. New Psychoactive Substances (NPS) reported During the 2020/2 round of ICE, participating laboratories provided information on NPS that had been identified in their laboratories. In total there were 63 reports of 45 substances. As shown in Figure 2, the most commonly reported substances were synthetic cannabinoids (27%) and substances belonging to a group known as “other substances” (27%). These substances are structurally diverse and do not fit into the categories mentioned in the UNODC Early Warning Advisory on NPS.

Figure 2. Distribution of classes of NPS reported by ICE laboratories during the 2020/2 round of ICE

In terms of the mode of action of the NPS reported by ICE participants, the predominant substances reported were synthetic cannabinoid receptor agonists (27%) followed by dissociatives (18%) and hallucinogens (18%) as shown in Figure 3.

Figure 3. Distribution of NPS reported by ICE participants in the 2020/2 round of ICE according to the

mode of action

27%

13%

27%

9%

17%

5% 2%

Synthetic cannabinoids

Synthetic cathinones

Other substances

Phenethylamines

Phencyclidine-type substances

Tryptamines

Plant-based substances

27%

15%

18%

6%

18%

16%

Synthetic cannabinoid receptor agonists

Stimulants

Hallucinogens

Opioids

Dissociatives

Sedatives/Hypnotics



Page 10 of 62

ICE 2020/2-BS

The substances most often reported by ICE participants were ketamine, MDMB-4en-PINACA and

flubromazolam. While ketamine is currently not under international control, MDMB-4en-PINACA and

flubromazolam were placed under international control under Schedule II and IV, respectively, of the

Convention on Psychotropic Substances, 1971, at the 64th session of the Commission on Narcotic Drugs

in April 2021. These decisions will come into force on 7 December 2021.

Name Convention Schedule Effective date of

international control

Flubromazolam 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]-triazolo[4,3-a][1,4]diazepine

1971 IV 7th December 2021

Ketamine 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one

Currently not under international control

MDMB-4en-PINACA methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate

1971 II 7th December 2021

For further details on these substances and others reported to the UNODC Early Warning Advisory, ICE

participants can log on to the UNODC ICE portal, www.unodc.org/lss, and select the icon for the Early

Warning Advisory on New Psychoactive substances as shown below.



Page 11 of 62

ICE 2020/2-BS

6. Summary of responses for Test Sample-1

The summary of responses of all 84 participating laboratories for the identification of BS-1:

Correct identification of Test Sample-1:

False positives for Test Sample-1 (technique(s) used):

False negatives for Test Sample-1 with respect to Morphine (technique(s) used):

Round Code Tech Code Round Code Tech Code 55O3RU 180, 190 J0E7UI 180 5ZE565 230 JFDHCS 180

AXDW2N 180 JMIFJG 180 BIDPSO 180, 231 JOXEMT 231

BOCUHG 231 LCXPWI 150, 180 DEEJ5E 180 O66Z5F 150 DZYOGL 180 REBSFB 180 EENW2Z 180 SW25NX 231 GGCGG3 231 T7ZWMT 180, 231 GRIPEY 180 VUASIY 180

Analysis not performed for Test Sample-1 with respect to Morphine:

6UPYUO, 8Q9HHM, 9P9B97, AQAYT9, HJCDJ2, JMJLE1, LAAAAA, MCZMMA, PDDDDD, PJ6NX9,

Q33R30 and W8VSHC.

Frequency of use of screening, identification and quantification techniques:

Test Sample 1: Response Summary

No of Participants: 84 (Qualitative); 0 (Quantitative)

Technique 100 110 142 150 160 161 170 180 190 210 230 231

Screening (No.) 1 50 1 0 0 1 0 18 0 1 6 14

(%) 1.2 59.5 1.2 0.0 0.0 1.2 0.0 21.4 0.0 1.2 7.1 16.7

Identification (No.) 0 5 0 4 1 5 1 66 1 1 10 40

(%) 0.0 6.0 0.0 4.8 1.2 6.0 1.2 78.6 1.2 1.2 11.9 47.6

Quantification (No.) 0 0 0 0 0 0 0 0 0 0 0 0

(%) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Substance Name Number of laboratories Percentage Morphine 52 61.9%

Round Code Substance Reported Tech Code 55O3RU Benzodiazepine 180, 190 LHZ8CT Benzoylecgonine, oxymorphone 231



Page 12 of 62

ICE 2020/2-BS





False negatives for Test Sample-2 with respect to Buprenorphine (and/or metabolite)

(technique(s) used):

Round Code Tech Code

55O3RU 180, 190 CAAEEE 180, 230 DZYOGL 180 GRIPEY 180 U4DAAJ 180, 231 UOKKUT 180

Analysis not performed for Test Sample-2 with respect to Buprenorphine (and metabolite):

5CHXK3, 5ZE565, 6UPYUO, 9NNWNO, 9P9B97, FCUPDY, GTNYPU, PJ6NX9, QDFCD8, REBSFB and VUASIY




Technique 100 110 142 150 160 161 170 180 190 210 230 231

Screening (No.) 1 50 1 0 0 1 0 18 0 1 6 14

(%) 1.2 59.5 1.2 0.0 0.0 1.2 0.0 21.4 0.0 1.2 7.1 16.7


(%) 0.0 6.0 0.0 4.8 1.2 6.0 1.2 78.6 1.2 1.2 11.9 47.6


(%) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.0 0.0 3.6 3.6 57.1

Substance Name Number of laboratories Percentage Buprenorphine 66 78.6%

Norbuprenorphine 47 56.0% At least one component 67 79.8%

Round Code Substance Reported Tech Code

55O3RU Benzodiazepine 180, 190

B3EBPD Nordazepam 230

CAAEEE Paracetamol 180, 230



Page 13 of 62

ICE 2020/2-BS

Z-Score Report per Sample per Substance:

Round: 2020/2

Substance: BS-2; Buprenorphine

-2.4

5

-1.5

5

-1.4

5 -1.0

9

-0.8

4

-0.7

8

-0.7

8 -0.3

7

-0.3

0

-0.2

8

-0.1

6

-0.1

4

-0.1

3

-0.1

2

-0.1

0

0.0

4

0.0

5

0.1

6

0.3

4

0.3

9

0.5

4

0.5

5

0.5

7 0.9

6 1.4

5 1.7

6

6.9

8

16

.26

-4.00

-3.00

-2.00

-1.00

0.00

1.00

2.00

3.00

4.00

90

YC0

Z

LHZ8

CT

GG

CG

G3

EEN

W2

Z

JW3

GX

I

6SJ

6SS

SW2

5N

X

DM

UL5

S

BO

CU

HG

MC

ZMM

A

8V

4YG

Y

8H

6FT

6

LGN

UV

H

VLN

X9

X

YYX

EXU

HC

HYZ

Y

MFP

KC

L

0R

3C

HB

AP

EFD

F

HJC

DJ2

T7ZW

MT

DEE

J5E

AQ

AYT

9

66

6K

D9

E66

6O

G

X2

CTX

X

LPN

77

A

QM

PZY

H

Z-scores can be interpreted by participants in line with ISO 13528:2015*, section 9.4.2 as follows: IzI ≤ 2.00 is considered to be acceptable 2.00 < IzI < 3.00 is considered to be questionable (or warning signal) IzI ≥ 3.00 is considered to be unacceptable (or action signal)

A single action signal or warning signal in two successive rounds shall be taken that an anomaly has occurred that requires investigation.

Robust mean: 885 ng/mL Robust SD: 287 ng/mL Robust CV%: 32.4%

Prepared conc.: 920 ng/mL Max reported: 5549 ng/mL Min reported: 182 ng/mL No of labs: 28



Page 14 of 62

ICE 2020/2-BS


Round: 2020/2

Substance: BS-2; Norbuprenorphine

-1.5

7

-1.5

7

-0.9

2

-0.9

2 -0.5

6

-0.5

3

-0.3

0

-0.2

5

-0.2

1

-0.1

3

0.0

1

0.1

2

0.1

4

0.2

3 0.5

9

0.6

3

0.6

8

1.4

1 1.8

5

10

.05

-4.00

-3.00

-2.00

-1.00

0.00

1.00

2.00

3.00

4.00

GG

CG

G3

90

YC0

Z

EEN

W2

Z

DM

UL5

S

0R

3C

HB

8V

4YG

Y

6SJ

6SS

LHZ8

CT

T7ZW

MT

BO

CU

HG

JW3

GX

I

SW2

5N

X

MC

ZMM

A

YYX

EXU

HJC

DJ2

HC

HYZ

Y

LGN

UV

H

X2

CTX

X

AP

EFD

F

LPN

77

A







Page 15 of 62

ICE 2020/2-BS




Page 16 of 62

ICE 2020/2-BS

Z-Scores for Test Sample-2

Code

Buprenorphine

Code

Norbuprenorphine

Concentration (ng/ml)

Deviation from robust

average (ng/ml)

z-score Concentration (ng/ml)


average (ng/ml)

z-score

90YC0Z 182 -703 -2.45 GGCGG3 208 -633 -1.57

LHZ8CT 440 -445 -1.55 90YC0Z 208 -633 -1.57

GGCGG3 470 -415 -1.45 EENW2Z 469 -372 -0.92

EENW2Z 571 -314 -1.09 DMUL5S 470 -371 -0.92

JW3GXI 644 -241 -0.84 0R3CHB 615 -226 -0.56

6SJ6SS 660 -225 -0.78 8V4YGY 629 -212 -0.53

SW25NX 662 -223 -0.78 6SJ6SS 720 -121 -0.30

DMUL5S 780 -105 -0.37 LHZ8CT 740 -101 -0.25

BOCUHG 800 -85 -0.30 T7ZWMT 755 -86 -0.21

MCZMMA 806 -79 -0.28 BOCUHG 790 -51 -0.13

8V4YGY 840 -45 -0.16 JW3GXI 846 5 0.01

8H6FT6 846 -39 -0.14 SW25NX 889 48 0.12

LGNUVH 849 -36 -0.13 MCZMMA 897 56 0.14

VLNX9X 850 -35 -0.12 YYXEXU 934 93 0.23

YYXEXU 855 -30 -0.10 HJCDJ2 1079 238 0.59

HCHYZY 896 11 0.04 HCHYZY 1094 253 0.63

MFPKCL 900 15 0.05 LGNUVH 1114 273 0.68

0R3CHB 930 45 0.16 X2CTXX 1410 569 1.41

APEFDF 982 97 0.34 APEFDF 1587 746 1.85

HJCDJ2 997 112 0.39 LPN77A 4889 4048 10.05

T7ZWMT 1039 154 0.54 DEEJ5E 1042 157 0.55 AQAYT9 1047 162 0.57 666KD9 1159 274 0.96 E666OG 1300 415 1.45 X2CTXX 1390 505 1.76 LPN77A 2887 2002 6.98 QMPZYH 5549 4664 16.26



Page 17 of 62

ICE 2020/2-BS





False negatives for Test Sample-3 with respect to Nordazepam (technique(s) used):

Round Code Tech Code 55O3RU 180, 190 O66Z5F 150 XEHBYJ 150

Analysis not performed for Test Sample-3 with respect to Nordazepam:

6SOTQX, 6UPYUO, 8Q9HHM, GTNYPU and LHZ8CT




Technique 100 110 142 150 160 161 170 180 190 210 230 231

Screening (No.) 1 50 1 0 0 1 0 18 0 1 6 14

(%) 1.2 59.5 1.2 0.0 0.0 1.2 0.0 21.4 0.0 1.2 7.1 16.7


(%) 0.0 6.0 0.0 4.8 1.2 6.0 1.2 78.6 1.2 1.2 11.9 47.6


(%) 0.0 0.0 0.0 0.0 2.9 2.9 0.0 41.2 0.0 0.0 2.9 41.2

Substance Name Number of laboratories Percentage Nordazepam 76 90.5%

Round Code Substance Reported Tech Code 55O3RU Benzenethanamine derivative 180, 190

B3EBPD Buprenorphine 230

LHZ8CT MDPV 180, 231

O66Z5F Temazepam 150

VUASIY Alprazolam 180

XEHBYJ Temazepam 150



Page 18 of 62

ICE 2020/2-BS


Round: 2020/2

Substance: BS-3; Nordazepam





-1.4

0

-1.2

1

-1.0

1

-0.9

2

-0.9

2

-0.7

8

-0.7

6

-0.7

5

-0.7

5

-0.5

2

-0.5

2

-0.5

0

-0.3

9

-0.3

9

-0.3

4

-0.2

8

-0.2

4

-0.2

4

-0.1

1

-0.1

1

-0.1

1

-0.0

3

0.1

6

0.2

9

0.3

3 0.5

9 0.8

5 1.0

8 1.4

7 1.8

0

2.6

5

3.3

6

7.3

8

34

.11

-4.00

-3.00

-2.00

-1.00

0.00

1.00

2.00

3.00

4.00

8V

4YG

Y

BO

CU

HG

QD

FCD

8

0R

3C

HB

T7ZW

MT

QM

PZY

H

SW2

5N

X

REB

SFB

6SJ

6SS

LGN

UV

H

8H

6FT

6

RM

YQA

R

JMJL

E1

JW3

GX

I

AP

EFD

F

90

YC0

Z

GG

CG

G3

VLN

X9

X

MFP

KC

L

HC

HYZ

Y

66

6K

D9

YYX

EXU

8T2

0G

0

AQ

AYT

9

EEN

W2

Z

LPN

77

A

DM

UL5

S

E66

6O

G

DEE

J5E

X2

CTX

X

HJC

DJ2

DZY

OG

L

U4

DA

AJ

VU

ASI

Y



Page 19 of 62

ICE 2020/2-BS




Page 20 of 62

ICE 2020/2-BS


Code

Nordazepam



average (ng/ml)

z-score

8V4YGY 217 -244 -1.40

BOCUHG 250 -211 -1.21

QDFCD8 285 -176 -1.01

0R3CHB 300 -161 -0.92

T7ZWMT 301 -160 -0.92

QMPZYH 325 -136 -0.78

SW25NX 328 -133 -0.76

REBSFB 330 -131 -0.75

6SJ6SS 330 -131 -0.75

LGNUVH 370 -91 -0.52

8H6FT6 370 -91 -0.52

RMYQAR 374 -87 -0.50

JMJLE1 393 -68 -0.39

JW3GXI 393 -68 -0.39

APEFDF 402 -59 -0.34

90YC0Z 413 -48 -0.28

GGCGG3 420 -41 -0.24

VLNX9X 420 -41 -0.24

MFPKCL 442 -19 -0.11

HCHYZY 442 -19 -0.11

666KD9 442 -19 -0.11

YYXEXU 456 -5 -0.03

8T20G0 490 29 0.16

AQAYT9 512 51 0.29

EENW2Z 518 57 0.33

LPN77A 565 104 0.59

DMUL5S 610 149 0.85

E666OG 650 189 1.08

DEEJ5E 719 258 1.47

X2CTXX 776 315 1.80

HJCDJ2 925 464 2.65

DZYOGL 1050 589 3.36

U4DAAJ 1753 1292 7.38

VUASIY 6430 5969 34.11



Page 21 of 62

ICE 2020/2-BS





False negatives for Test Sample-4 with respect to MDMA (technique(s) used):

Round Code Tech Code 55O3RU 180, 190 AN3H29 180 DZYOGL 180 EENW2Z 180 GRIPEY 180 GVGEP9 230 O2A2BN 210

Analysis not performed for Test Sample-4 with respect to MDMA:

FCUPDY




Technique 100 110 142 150 160 161 170 180 190 210 230 231

Screening (No.) 1 50 1 0 0 1 0 18 0 1 6 14

(%) 1.2 59.5 1.2 0.0 0.0 1.2 0.0 21.4 0.0 1.2 7.1 16.7


(%) 0.0 6.0 0.0 4.8 1.2 6.0 1.2 78.6 1.2 1.2 11.9 47.6


(%) 0.0 2.9 0.0 0.0 0.0 0.0 0.0 38.2 0.0 0.0 2.9 47.1

Substance Name Number of laboratories Percentage MDMA 76 90.5%

Round Code Substance Reported Tech Code 55O3RU Opiates 180, 190

CAAEEE Quetiapine 180, 230

DZYOGL Amfetamine 180

GRIPEY Metamfetamine 180

GTNYPU 11-nor-∆9-THC-9-carboxylic acid, THC 180

GVGEP9 Morphine 230

O2A2BN Mephedrone 210



Page 22 of 62

ICE 2020/2-BS


Round: 2020/2

Substance: BS-4; MDMA





-2.6

9 -2.2

4

-1.4

8

-1.4

8

-1.2

1

-1.0

0 -0.6

2

-0.6

2

-0.6

1

-0.5

7

-0.4

4

-0.3

1

-0.2

2

-0.1

8

-0.1

5

-0.1

4

0.0

9

0.1

2

0.1

3

0.1

6

0.2

5

0.3

2

0.3

5

0.3

9

0.4

3

0.4

7 0.7

2

0.7

4 1.0

6

1.0

9 1.3

2

1.4

4

1.4

5 1.9

2

-4.00

-3.00

-2.00

-1.00

0.00

1.00

2.00

3.00

4.00

GG

CG

G3

QM

PZY

H

VU

ASI

Y

O6

6Z5

F

JW3

GX

I

66

6K

D9

6SO

TQX

LGN

UV

H

MC

ZMM

A

AQ

AYT

9

REB

SFB

6SJ

6SS

YYX

EXU

MFP

KC

L

U4

DA

AJ

8H

6FT

6

T7ZW

MT

8T2

0G

0

SW2

5N

X

90

YC0

Z

HJC

DJ2

HC

HYZ

Y

BO

CU

HG

DM

UL5

S

VLN

X9

X

LHZ8

CT

QD

FCD

8

X2

CTX

X

AP

EFD

F

DEE

J5E

0R

3C

HB

E66

6O

G

8V

4YG

Y

LPN

77

A



Page 23 of 62

ICE 2020/2-BS




Page 24 of 62

ICE 2020/2-BS


Code

MDMA



average (ng/ml)

z-score

GGCGG3 189 -691 -2.69

QMPZYH 305 -575 -2.24

VUASIY 500 -380 -1.48

O66Z5F 500 -380 -1.48

JW3GXI 569 -311 -1.21

666KD9 623 -257 -1.00

6SOTQX 720 -160 -0.62

LGNUVH 721 -159 -0.62

MCZMMA 724 -156 -0.61

AQAYT9 733 -147 -0.57

REBSFB 766 -114 -0.44

6SJ6SS 800 -80 -0.31

YYXEXU 824 -56 -0.22

MFPKCL 834 -46 -0.18

U4DAAJ 840 -40 -0.15

8H6FT6 844 -36 -0.14

T7ZWMT 902 22 0.09

8T20G0 910 30 0.12

SW25NX 914 34 0.13

90YC0Z 921 41 0.16

HJCDJ2 943 63 0.25

HCHYZY 961 81 0.32

BOCUHG 970 90 0.35

DMUL5S 980 100 0.39

VLNX9X 990 110 0.43

LHZ8CT 1000 120 0.47

QDFCD8 1065 185 0.72

X2CTXX 1070 190 0.74

APEFDF 1151 271 1.06

DEEJ5E 1160 280 1.09

0R3CHB 1220 340 1.32

E666OG 1250 370 1.44

8V4YGY 1252 372 1.45

LPN77A 1373 493 1.92



Page 25 of 62

ICE 2020/2-BS

10. ANNEX 1: Participants’ results for Test Sample-1

Identified substances for Test Sample 1

Code Identified Substances

0R3CHB Morphine

4GKVKL Morphine

55O3RU Caffeine and Benzodiazepine drug

5CHXK3 Morphine

666KD9 Morphine

6SJ6SS morphine

6SOTQX Morphine

6UPYUO NONE

7BXXXX Morphine

7V7ZMZ MORPHINE

8H6FT6 Morphine.

8Q9HHM Opiates

8T20G0 Morphine

90YC0Z morphine

9NNWNO Morphine

9NQ999 Morphine

AN3H29 Morphine

APEFDF morphine

AQAYT9 -

B3EBPD morphine

CAAEEE MORPHINE

DD6DWV morphine

DEEJ5E none

DMUL5S Morphine

E666OG Morphine

EENDPO Morphine

GTNYPU MORPHINE

GVGEP9 morphin

H8PYU5 Morphine

HCHYZY MORPHINE

HHT9JH morphine (total)

HJCDJ2 -

J0E7UI -

JFDHCS None

JOXEMT NO

JW3GXI Morphine

LCXPWI no



Page 26 of 62

ICE 2020/2-BS


LGNUVH MORPHINE

LHZ8CT morphine, oxymorphone, benzoylecgonine

LPN77A morphine

MFPKCL Morphine

O2A2BN Morphine

O66Z5F none

PJ6NX9 None

PPQ4MN Morphine

QBVFBW Morphine

QDFCD8 Morphine

RMYQAR Morphine, total

T90OIT Morphine

TCP07X Morphine (Total)

U4DAAJ Morphine

UOKKUT Morphine (Total)

VLNX9X Morphine

W8VSHC No drugs

X2CTXX Morphine

XEHBYJ morphine traces

Y2QOYO Morphine

YYXEXU Morphine

ZQFW61 Morphine



Page 27 of 62

ICE 2020/2-BS

Statement of findings for Test Sample 1

Code Morphine (Total)

0R3CHB + -

4GKVKL + In the urine sample analyzed was detected and confirmed the presence of morphine.

55O3RU - On TLC & GC-MS examination, sample was found to contain Caffeine and Benzodiazepine drug.

5CHXK3 + Morphine was detected in sample BS-1

5ZE565 -

666KD9 + Specimen 2020/2/BS-1 is positive for drug Morphine

6SJ6SS +

6SOTQX + Consistent with use of morphine or heroin.

6UPYUO ANP SAMPLE 2020/2/BS-1 FOUND NOT TO CONTAIN ANY DRUGS

7BXXXX + Non-recent heroin/morphine use or prior consumption of food product containing poppy seeds

7V7ZMZ +

8H6FT6 + Probable medicinal use of morphine.

8Q9HHM ANP Presence of opiates in the sample 2020/2/BS-1. N.B: The analytical technique used is a semi-quantitaive technique; The opiates's amount found = 146 ng/ml. However, The analysis must be confirmed by a chromatographic method.

8T20G0 + Morphine results reported as free morphine

8V4YGY +

90YC0Z + this person consumed morphine or poppy seeds

9NNWNO +

9NQ999 + In the sample analyzed morphine was found.

9P9B97 ANP No common basic and acid drugs were detected in sample 2020/2/BS-1



Page 28 of 62

ICE 2020/2-BS


A65OOQ +

AN3H29 + The coincidence between the relative retention time and mass-fragmentograms from a reference standard analyzed at the same conditions that the biological sample, indicates the detection of morphine and caffeine.

APEFDF + Presence of morphine

AQAYT9 ANP -

AXDW2N -

B3EBPD + morphine was found

BIDPSO - Examination and analyses performed on Exhibit "2020/2/BS1" did not reveal any positive findings of toxicological significance.

BOCUHG -

CAAEEE + CAFFEINE

DD6DWV + positive

DEEJ5E - blank control sample

DMUL5S +

DZYOGL -

E666OG + Morphine+ caffeine

EENDPO + Morphine was detected in BS-1 Sample.

EENW2Z - The simple not contains controlled drugs

FCUPDY +

GGCGG3 -

GRIPEY -

GTNYPU +

GVGEP9 +

H8PYU5 + It indicates the intake of morphine or the past use of heroin.



Page 29 of 62

ICE 2020/2-BS


HCHYZY + La morphine est un analgésique (effet analgésique) de la famille des opiacés. La morphine est une molécule alcaloïde extraite de L'Opium. Elle agit directement sur le système nerveux central pour diminuer la sensation de douleur. elle est classée stupéfiant dans la plupart des pays

HHT9JH + in the urine morphine and caffeine were identified

HJCDJ2 ANP -

J0E7UI - we not found contain controlled drugs in BS-01

JFDHCS - No drugs that have been found in this test sample.

JMIFJG -

JMJLE1 ANP Drugs were not detected in 2020/2/BS-1

JOXEMT - no drug was identified - BLANK SAMPLE

JW3GXI + Morphine was detected in 2020/2/BS-1 sample.

KWLGGO +

LAAAAA ANP

LCXPWI -

LGNUVH + Morphine is detected in sample number one by LC-MS/MS

LHZ8CT + Negative (all analytes under cut-off)

LPN77A + morphine 60.03 ng/ml

MCZMMA ANP

MFPKCL +

O2A2BN +

O66Z5F -

PDDDDD ANP No drug detected

PJ6NX9 ANP None

PPQ4MN +



Page 30 of 62

ICE 2020/2-BS


Q33R30 ANP No common drugs were detected in Sample 2020/2/BS-1.

QBVFBW +

QDFCD8 + Only free morphine was measured

QMPZYH +

REBSFB - Test sample 2020/2 BS-1 does not contain controlled drugs (Metamfetamine, Amfetamine, 11- nor-∆9-THC-9-carboxylic acid, 3,4-Methylenedioxymetamfetamine (MDMA), Morphine, Codeine, Oxazepam, Nordazepam and Benzoylecgonine), therefore Negative for Screening and Confirmatory analyses.

RMYQAR + Morphine, total ~0.09mg/L

SW25NX -

T7ZWMT - we only found traces of caffeine and theobromine

T90OIT + In sample BS-1 the drug morphine (total) was detected.

TCP07X +

U4DAAJ +

UOKKUT +

V4VTFQ +

VLNX9X +

VUASIY -

W8VSHC ANP

X2CTXX + 2020/2/BS-1 was containing morphine

XEHBYJ + Sample 2020/2/BS-1 contain morphine traces

Y2QOYO + Analytical Adverse Finding for Morphine

YYXEXU + Morphine

ZQFW61 + Morphine detected



Page 31 of 62

ICE 2020/2-BS

Identification methods for Test Sample 1

Analytical Technique Codes

Code 100 110 142 150 160 161 170 180 190 230 231 210

0R3CHB I SI

4GKVKL SI SI I

55O3RU SI I

5CHXK3 S SI SI

5ZE565 I SI

666KD9 S I I I

6SJ6SS S I SI

6SOTQX I SI

6UPYUO SI

7BXXXX SI SI

7V7ZMZ S I

8H6FT6 I I SI

8Q9HHM SI SI Immunochromatographic rapid tests

8T20G0 S I I

8V4YGY S I I

90YC0Z S I I

9NNWNO I

9NQ999 S I

9P9B97 I

A65OOQ S I I

AN3H29 I

APEFDF S S SI I

AQAYT9 S I

AXDW2N S I

B3EBPD I I S COBAS

BIDPSO I I

BOCUHG S SI

CAAEEE SI I

DD6DWV SI SI SFC-MS/MS

DEEJ5E SI

DMUL5S S I I

Legend: S ... used for Screening I ... used for Identification SI ... used for both



Page 32 of 62

ICE 2020/2-BS

Code 100 110 142 150 160 161 170 180 190 230 231 210

DZYOGL S I

E666OG S I SI

EENDPO I

EENW2Z S I

FCUPDY S I

GGCGG3 S I

GRIPEY S I

GTNYPU I

GVGEP9 S I

H8PYU5 S I SI

HCHYZY S I I

HHT9JH SI

HJCDJ2 S I I

J0E7UI S I

JFDHCS I I S Chemical immunoassay techniques

JMIFJG S I

JMJLE1 SI SI

JOXEMT SI

JW3GXI S I I I

KWLGGO S I I

LAAAAA S I SI

LCXPWI I I

LGNUVH S I I

LHZ8CT S I I

LPN77A I SI I

MCZMMA I I S KIMS and LC-Orbitrap MS

MFPKCL S I UHPLC-QTOF

O2A2BN SI LC TOFMS

O66Z5F I SI Dipro Drug Lab screen

PDDDDD I

PJ6NX9 I

PPQ4MN I

Q33R30 SI

QBVFBW S I I

QDFCD8 SI

QMPZYH S I I

REBSFB I S DTK



Page 33 of 62

ICE 2020/2-BS

Code 100 110 142 150 160 161 170 180 190 230 231 210

RMYQAR S I I

SW25NX S I

T7ZWMT SI I

T90OIT SI SI

TCP07X I

U4DAAJ I I S immunochromatographic test

UOKKUT S I

V4VTFQ SI S Immunochromatographic test

VLNX9X S I SI

VUASIY S I

W8VSHC S I

X2CTXX S I

XEHBYJ S I S Randox Biochip Technology

Y2QOYO SI SI

YYXEXU S I SI

ZQFW61 SI



Page 34 of 62

ICE 2020/2-BS

11. ANNEX 2: Participants’ results for Test Sample-2 Identified substances for Test Sample 2


0R3CHB Buprenorphine, Norbuprenorphine

4GKVKL Buprenorphine, Norbuprenorphine

55O3RU Caffeine and Benzodiazepine drug

666KD9 Buprenorphine

6SJ6SS buprenorphine, norbuprenorphine

6SOTQX Buprenorphine and Norbuprenorphine

6UPYUO NONE

7BXXXX Buprenorphine/norbuprenorphine

7V7ZMZ BUPRENORPHINE, NORBUPRENORPHINE

8H6FT6 Buprenorphine, norbuprenorphine.

8Q9HHM Buprenorphine

8T20G0 Buprenorphine and norbuprenorphine

90YC0Z buprenorphine

9NQ999 Buprenorphine, Norbuprenorphine

AN3H29 Burprenorphine

APEFDF buprenorphine and norbuprenorphine

AQAYT9 Buprenorphine

AXDW2N Buprenorphine

B3EBPD Nordazepam

BIDPSO Buprenorphine and Norbuprenorphine

BOCUHG Buprenorphine and Norbuprenorphine

DD6DWV buprenorphine + norbuprenorphine

DEEJ5E buprenorphine

DMUL5S Buprenorphine, norbuprenorphine

E666OG Buprenorphine

EENDPO Burprenorphine

EENW2Z Buprenorphine

GGCGG3 buprenorphine, norbuprenorphine

GVGEP9 norbuprenorphine and buprenorphine

H8PYU5 Buprenorphine and Norbuprenorphine

HCHYZY Buprénorphine et norbuprénorphine

HHT9JH (nor)buprenorphine

HJCDJ2 Buprenorphine, Norbuprenorphine

J0E7UI buprenorphine and norbuprenorphine

JFDHCS Buprenophine and Norbuprenophine

JMIFJG Buprenorphine + Norbuprenorphine

JMJLE1 Buprenorphine



Page 35 of 62

ICE 2020/2-BS


JOXEMT BUPRENORPHINE AND NORBUPRENORPHINE

JW3GXI Buprenorphine and norbuprenorphine

LAAAAA BUPRENORPHINE et NORBUPRENORPHINE

LCXPWI Buprenorphine, norbuprenorphine

LGNUVH BUPRENORPHINE and NORBUPRENORPHINE

LHZ8CT buprenorphine

LPN77A buprenorphine, norbuprenorphine

MCZMMA Buprenophine, Norburprenorphine

MFPKCL Buprenorphine and Norbuprenorphine

O2A2BN Buprenorphine

O66Z5F Buprenorfine

PDDDDD Buprenorphine

PJ6NX9 None

PPQ4MN Buprenorphine

Q33R30 Buprenorphine

QBVFBW Buprenorphine

RMYQAR Buprenorphine,Norbuprenorphine

SW25NX Norbup and Bup

T7ZWMT buprenorphine and norbuprenorphine

T90OIT Buprenorphine and norbuprenorphine

TCP07X Buprenorphine

VLNX9X Buprenorphine

W8VSHC Buprenorphine

X2CTXX Buprenorphine and Norbuprenorphine

XEHBYJ buprenorphine,norbuprenorphine

Y2QOYO Norbuprenorphine

YYXEXU Norbuprenorphine, Buprenorphine

ZQFW61 Buprenorphine and Norbuprenorphine



Page 36 of 62

ICE 2020/2-BS


Code Buprenorphine Norbuprenorphine

0R3CHB + + -

4GKVKL + + In the urine sample analyzed was detected and confirmed the presence of Buprenorphine and Norbuprenorphine.

55O3RU - - On TLC & GC-MS examination, sample was found to contain Caffeine and Benzodiazepine drug.

5CHXK3 ANP ANP

5ZE565 ANP ANP

666KD9 + ANP Specimen 2020/2/BS-2 is positive for drug Buprenorphine

6SJ6SS + +

6SOTQX + + Concentrations of buprenorphine and metabolite were both >200ng/mL, these are high concentrations and consistent with use of buprenorphine.

6UPYUO ANP ANP SAMPLE 2020/2/BS-2 FOUND NOT TO CONTAIN ANY DRUGS

7BXXXX + + Immunoassay method used so neither analyte unequivocally confirmed (assay has cross-reactivity to both)

7V7ZMZ + +

8H6FT6 + + Use of buprenorphine.

8Q9HHM + ANP Presence of Buprenorphine in the sample 2020/2/BS-2. N.B: The analysis must be confirmed by a chromatographic method to quantify the found substance.

8T20G0 + + Only qualitative analysis has been carried out

8V4YGY + +

90YC0Z + + this person consumed buprenorphine

9NNWNO ANP ANP The substances that were tested are not present.

9NQ999 + + In the sample analyzed Buprenorphine and Norbuprenorphine were found.

9P9B97 ANP ANP No common basic and acid drugs were detected in sample 2020/2/BS-2



Page 37 of 62

ICE 2020/2-BS


A65OOQ + +

AN3H29 + - The coincidence between the relative retention time and mass-fragmentograms from a reference standard analyzed at the same conditions that the biological sample, indicates the detection of Burprenorphine and caffeine.

APEFDF + + Presence of buprenorphine and its metabolite norbuprenorphine

AQAYT9 + ANP Buprenorphine was found qualitatively using GC-MS then confirmed quantitively using LC/MS/MS

AXDW2N + ANP Buprenorphine was identified by GC/MS analysis

B3EBPD + - nordazepam was found

BIDPSO + + Buprenorphine is an opioid medication. Norbuprenorphine is a metabolite of buprenorphine.

BOCUHG + + Positive to Buprenorphine and its metabolite Norbuprenorphine

CAAEEE - - CAFFEINE, PARACETAMOL

DD6DWV + + positive

DEEJ5E + ANP subject in substitution treatment

DMUL5S + +

DZYOGL - -

E666OG + ANP Buprenorphine

EENDPO + ANP Burprenorphine was detected in BS-2 Sample.

EENW2Z + + The simple contains Buprenorphine and Norbuprenorphine

FCUPDY ANP ANP

GGCGG3 + + recent intake of buprenorphine.No information on the conditions of the subject at the time of sample collection.

GRIPEY - -

GTNYPU ANP ANP

GVGEP9 + +



Page 38 of 62

ICE 2020/2-BS


H8PYU5 + + It indicates the intake of buprenorphine. Norbuprenorphine is the metabolite of buprenorphine.

HCHYZY + + La buprénorphine (DCI) est un médicament, agoniste partiel (ou agoniste-antagoniste) morphinique et se fixe au niveau des récepteurs cérébraux µ et k5. Cette substance a d'abord été produite comme analgésique dans les années 1980. Le médicament est réglementé. Il a secondairement été utilisé pour le traitement substitutif de la dépendance aux opiacés. En France, il est principalement utilisé dans cette indication à haut dosage actuellement.

HHT9JH + + in the urine buprenorphine en metabolite norbuprenorphine, caffeine were identified

HJCDJ2 + + screening and quantitation by GC-MS

J0E7UI + + we found buprenorphine as psychotropic substance and norbuprenorphine as uncontrolled substance

JFDHCS + + The drugs that have been found are synthetic opiates (Buprenophine and Norbuprenophine) that are confirmed by GC/MS analysis thechniques.

JMIFJG + +

JMJLE1 + ANP Buprenorphine was detected in 2020/2/BS-2

JOXEMT + + NORBUPRENORPHINE AND BUPRENORPHINE WERE IDENTIFIED IN THE SAMPLE 2

JW3GXI + + Buprenorphine and norbuprenorphine were detected in 2020/2/BS-2 sample.

KWLGGO + +

LAAAAA + + Il a été détecté la présence de la Buprenorphine et la Norbuprenorphine dans l'échantillon analysé.

LCXPWI + +

LGNUVH + + Buprenorphine and norbuprenorphine are detected in sample number two by EIA, GC/MS, and LC- MS/MS

LHZ8CT + + Positive for buprenorphine and metabolite

LPN77A + + buprenorphine 2887 ng/ml norbuprenorphine 4889 ng/ml

MCZMMA + +

MFPKCL + +

O2A2BN + -



Page 39 of 62

ICE 2020/2-BS


O66Z5F + - Buprenorfine

PDDDDD + ANP Buprenorphine detected

PJ6NX9 ANP ANP None

PPQ4MN + ANP

Q33R30 + ANP Buprenorphine was detected in Sample 2020/2/BS-2.

QBVFBW + ANP

QDFCD8 ANP ANP

QMPZYH + +

REBSFB ANP ANP Test sample 2020/2 BS-2 does not contain controlled drugs (Metamfetamine, Amfetamine, 11- nor-∆9-THC-9-carboxylic acid, 3,4-Methylenedioxymetamfetamine (MDMA), Morphine, Codeine, Oxazepam, Nordazepam and Benzoylecgonine), therefore Negative for Screening and Confirmatory analyses.

RMYQAR + + Buprenorphine - Detected Norbuprenorphine - Detected

SW25NX + + Norbup is a metabolite of Bup

T7ZWMT + + we also found traces of caffeine and theobromine

T90OIT + + In sample BS-2 the drugs buprenorphine and norbuprenorphine were detected.

TCP07X + ANP

U4DAAJ - -

UOKKUT ANP -

V4VTFQ + -

VLNX9X + ANP

VUASIY ANP ANP

W8VSHC + ANP

X2CTXX + + 2020/2/BS-2 was containing Buprenorphine and Norbuprenorphine

XEHBYJ + + Sample 2020/2/BS-2 contain buprenorphine, norbuprenorphine



Page 40 of 62

ICE 2020/2-BS


Y2QOYO - + Analytical Adverse Finding for norbuprenorphine

YYXEXU + + Norbuprenorphine, Buprenorphine

ZQFW61 + + Buprenorphine and Norbuprenorphine detected



Page 41 of 62

ICE 2020/2-BS



Code 100 110 142 150 160 161 170 180 190 230 231 210

0R3CHB I SI

4GKVKL SI SI I

55O3RU SI I

5CHXK3 S SI SI

5ZE565 I SI

666KD9 S I I I

6SJ6SS S I SI

6SOTQX I SI

6UPYUO SI

7BXXXX SI SI

7V7ZMZ S I

8H6FT6 I I SI


8T20G0 S I I

8V4YGY S I I

90YC0Z S I I

9NNWNO I

9NQ999 S I

9P9B97 I

A65OOQ S I I

AN3H29 I

APEFDF S S SI I

AQAYT9 S I

AXDW2N S I

B3EBPD I I S COBAS

BIDPSO I I

BOCUHG S SI

CAAEEE SI I


DEEJ5E SI

DMUL5S S I I




Page 42 of 62

ICE 2020/2-BS

Code 100 110 142 150 160 161 170 180 190 230 231 210

DZYOGL S I

E666OG S I SI

EENDPO I

EENW2Z S I

FCUPDY S I

GGCGG3 S I

GRIPEY S I

GTNYPU I

GVGEP9 S I

H8PYU5 S I SI

HCHYZY S I I

HHT9JH SI

HJCDJ2 S I I

J0E7UI S I


JMIFJG S I

JMJLE1 SI SI

JOXEMT SI

JW3GXI S I I I

KWLGGO S I I

LAAAAA S I SI

LCXPWI I I

LGNUVH S I I

LHZ8CT S I I

LPN77A I SI I



O2A2BN SI LC TOFMS


PDDDDD I

PJ6NX9 I

PPQ4MN I

Q33R30 SI

QBVFBW S I I

QDFCD8 SI

QMPZYH S I I

REBSFB I S DTK



Page 43 of 62

ICE 2020/2-BS

Code 100 110 142 150 160 161 170 180 190 230 231 210

RMYQAR S I I

SW25NX S I

T7ZWMT SI I

T90OIT SI SI

TCP07X I


UOKKUT S I


VLNX9X S I SI

VUASIY S I

W8VSHC S I

X2CTXX S I


Y2QOYO SI SI

YYXEXU S I SI

ZQFW61 SI



Page 44 of 62

ICE 2020/2-BS



0R3CHB Nordazepam

4GKVKL Nordazepam

55O3RU Caffeine, Benzodiazepine drug, Benzenethanamine derivative

5CHXK3 Nordazepam

5ZE565 nordiazepam

666KD9 Nordazepam

6SJ6SS nodiazepam

6UPYUO NONE

7BXXXX Nordiazepam

7V7ZMZ NORDAZEPAM

8H6FT6 Nordiazepam.

8Q9HHM Benzodiazepines

8T20G0 Nordazepam

90YC0Z nordazepam

9NNWNO Nordazepam

9NQ999 Nordazepam

9P9B97 Nordazepam

AN3H29 Nordazepam

APEFDF nordiazepam

AQAYT9 Nordazepam

AXDW2N Nordazepam

B3EBPD buprenorphine

BIDPSO Nordazepam

BOCUHG Nordazepam

CAAEEE NORDAZEPAM

DD6DWV nordazepam

DEEJ5E nordiazepam

DMUL5S Nordazepam

DZYOGL nordazepam

E666OG Benzodiazepines

EENDPO Nordazepam

EENW2Z Nordazepam

GGCGG3 nordazepam

GRIPEY Нордазепам

GVGEP9 nordiazepam

H8PYU5 Nordiazepam

HCHYZY Nordazépam



Page 45 of 62

ICE 2020/2-BS


HHT9JH nordazepam

HJCDJ2 Nordazepam

J0E7UI Nordazepam

JFDHCS Nordazepam

JMIFJG Nordazepam

JMJLE1 Nordiazepam

JOXEMT NORDAZEPAM

JW3GXI Nordazepam

LAAAAA Nordazepam

LCXPWI Nordazepam

LGNUVH Nordazepam

LHZ8CT MPDV

LPN77A nordazepam

MCZMMA Nordiazepam

MFPKCL Nordazepam

O2A2BN Nordazepam

O66Z5F Benzodiazepines

PDDDDD Nordazepam

PJ6NX9 Nordazepam

PPQ4MN Nordazepam

Q33R30 Nordazepam

QBVFBW Nordazepam

QDFCD8 Nordazepam

REBSFB Nordazepam

RMYQAR Nordiazepam

SW25NX Nordazepam

T7ZWMT nordazepam

T90OIT Nordazepam

TCP07X Nordazepam

U4DAAJ Nordazepam

UOKKUT Nordazepam

VLNX9X nordazepam

VUASIY alprazolam, nordazepam

W8VSHC Nordiazepam

X2CTXX Nordiazepam

XEHBYJ temazepam

Y2QOYO Nordiazepam

YYXEXU Nordazepam

ZQFW61 Nordazepam



Page 46 of 62

ICE 2020/2-BS


Code Nordazepam

0R3CHB + -

4GKVKL + In the urine sample analyzed was detected and confirmed the presence of nordazepam.

55O3RU - On TLC & GC-MS examination, sample was found to contain Caffeine, Benzodiazepine drug, Benzenethanamine derivative

5CHXK3 + Nordazepam was detected in sample BS-3

5ZE565 + nordiazepam

666KD9 + Specimen 2020/2/BS-3 is positive for drug Nordazepam

6SJ6SS +

6SOTQX ANP

6UPYUO ANP SAMPLE 2020/2/BS-3 FOUND NOT TO CONTAIN ANY DRUGS

7BXXXX + Prior benzodiazepine use (N.B. no other benzos, such as oxazepam detected).

7V7ZMZ +

8H6FT6 + Use of some benzodiazepine type drug or drugs (e.g. chlordiazepoxide, diazepam, medazepam, tetrazepam).

8Q9HHM ANP Presence of Benzodiazepines in the sample 2020/2/BS-3. N.B: The analysis must be confirmed by a chromatographic method to identify and quantify the exact substance.

8T20G0 +

8V4YGY +

90YC0Z + this person consumed one of 1,4-benzodiazepines

9NNWNO +

9NQ999 + In the sample analyzed Nordazepam was found.

9P9B97 + Nordazepam was detected in sample 2020/2/BS-3

A65OOQ +



Page 47 of 62

ICE 2020/2-BS

Code Nordazepam

AN3H29 + The coincidence between the relative retention time and mass-fragmentograms from a reference standard analyzed at the same conditions that the biological sample, indicates the detection of Nordazepam and caffeine.

APEFDF + Presence of nordiazepam

AQAYT9 + Benzodiazepines was as a positive indicator in screening which then was analyzed quantitatively by LC/MS/MS to show that Nordazepam was present

AXDW2N + Nordazepam was identified by GC/MS analysis

B3EBPD + buprenorphine was found

BIDPSO + Nardazepam is a tranquilliser.

BOCUHG + Positivo to Nordazepam

CAAEEE + CAFFEINE

DD6DWV + positive

DEEJ5E + Subject assuming BDZ (diazepam)

DMUL5S +

DZYOGL + A solid phase extraction for benzodiazepines was performed and confirmed by a specific analysis method in GC/MS

E666OG + Nordazepam

EENDPO + Nordazepam was detected in BS-3 Sample.

EENW2Z + Nordazepam in concentration of 518.2+-8.8 ng/mL

FCUPDY +

GGCGG3 + recent intake of nordazepam. Possible presence in urine as metabolite of other benzodiazepines, although in absence of the parent compound.No information on the conditions of the subject at the time of sample collection.

GRIPEY +

GTNYPU ANP

GVGEP9 +

H8PYU5 + It indicates the past intake of diazepam or the intake of nordiazepam.



Page 48 of 62

ICE 2020/2-BS

Code Nordazepam

HCHYZY + Nordazepam est un dérivé de 1,4 benzodiazépine avec des propriétés amnésiantes, anticonvulsivantes, anxiolytique, relaxant musculaire et sédatives. Il s’agit d’un métabolite actif du diazépam, chlordiazépoxide, prazepam etc. utilisé principalement dans le traitement des troubles anxieux. Les effets secondaires courants du nordazepam incluent la somnolence et l'amnésie

HHT9JH + in the urine nordazepam and caffeine were identified

HJCDJ2 + screening with rapid test kit and quantitation by GC-MS

J0E7UI + we found Nordazepam as psychotropic substance

JFDHCS + The drug that has been found is Nordazepam. It belongs to the class of benzodiazepines.

JMIFJG +

JMJLE1 + 2020/2/BS-3 contains 393 ng/mL nordiazepam

JOXEMT + NORDAZEPAM WAS IDENTIFIED IN THE SAMPLE 3

JW3GXI + Nordazepam was detected in 2020/2/BS-3 sample.

KWLGGO +

LAAAAA + projection par confirmée par la technique HPLC

LCXPWI +

LGNUVH + Benzodiazepine is detected in sample number three by EIA, and confirmed by GC/MS, and LC- MS/MS as Nordazepam

LHZ8CT ANP Negative (MPDV under cut-off)

LPN77A + nordazepam 565 ng/ml

MCZMMA +

MFPKCL +

O2A2BN +

O66Z5F - Temazepam

PDDDDD + Nordazepam detected

PJ6NX9 + Nordazepam is a derivative of 1, 4-benzodiazepines and is prescribed in the First and Third Schedules (Psychotropic Substances), Poisons Act 1952.



Page 49 of 62

ICE 2020/2-BS

Code Nordazepam

PPQ4MN +

Q33R30 + Nordazepam was detected in Sample 2020/2/BS-3.

QBVFBW +

QDFCD8 +

QMPZYH +

REBSFB + Test sample 2020/2/BS-3 was found to contain controlled drugs for Nordazepam, therefore Positive for the Screening and Confirmatory analyses with concentration value of 329.87 ng/mL.

RMYQAR + Nordiazepam ~0.4mg/L

SW25NX + Nordazepam is a benzodiazepine

T7ZWMT + we also found traces of caffeine and theobromine

T90OIT + In sample BS-3 the metabolite nordazepam was detected.

TCP07X +

U4DAAJ +

UOKKUT +

V4VTFQ +

VLNX9X +

VUASIY +

W8VSHC +

X2CTXX + 2020/2/BS-3 was containing Nordiazepam

XEHBYJ - Sample 2020/2/BS-3 contain temazepam

Y2QOYO + Analytical Adverse Finding for nordiazepam

YYXEXU + Nordazepam

ZQFW61 + Nordazepam detected



Page 50 of 62

ICE 2020/2-BS



Code 100 110 142 150 160 161 170 180 190 230 231 210

0R3CHB I SI

4GKVKL SI SI I

55O3RU SI I

5CHXK3 S SI SI

5ZE565 I SI

666KD9 S I I I

6SJ6SS S I SI

6SOTQX I SI

6UPYUO SI

7BXXXX SI SI

7V7ZMZ S I

8H6FT6 I I SI


8T20G0 S I I

8V4YGY S I I

90YC0Z S I I

9NNWNO I

9NQ999 S I

9P9B97 I

A65OOQ S I I

AN3H29 I

APEFDF S S SI I

AQAYT9 S I

AXDW2N S I

B3EBPD I I S COBAS

BIDPSO I I

BOCUHG S SI

CAAEEE SI I


DEEJ5E SI

DMUL5S S I I




Page 51 of 62

ICE 2020/2-BS

Code 100 110 142 150 160 161 170 180 190 230 231 210

DZYOGL S I

E666OG S I SI

EENDPO I

EENW2Z S I

FCUPDY S I

GGCGG3 S I

GRIPEY S I

GTNYPU I

GVGEP9 S I

H8PYU5 S I SI

HCHYZY S I I

HHT9JH SI

HJCDJ2 S I I

J0E7UI S I


JMIFJG S I

JMJLE1 SI SI

JOXEMT SI

JW3GXI S I I I

KWLGGO S I I

LAAAAA S I SI

LCXPWI I I

LGNUVH S I I

LHZ8CT S I I

LPN77A I SI I



O2A2BN SI LC TOFMS


PDDDDD I

PJ6NX9 I

PPQ4MN I

Q33R30 SI

QBVFBW S I I

QDFCD8 SI

QMPZYH S I I

REBSFB I S DTK



Page 52 of 62

ICE 2020/2-BS

Code 100 110 142 150 160 161 170 180 190 230 231 210

RMYQAR S I I

SW25NX S I

T7ZWMT SI I

T90OIT SI SI

TCP07X I


UOKKUT S I


VLNX9X S I SI

VUASIY S I

W8VSHC S I

X2CTXX S I


Y2QOYO SI SI

YYXEXU S I SI

ZQFW61 SI



Page 53 of 62

ICE 2020/2-BS



0R3CHB 3,4-Methylenedioxymetamfetamine (MDMA)

4GKVKL MDMA

55O3RU Caffeine and Opiates

5CHXK3 3,4-Methylenedioxymetamfetamine (MDMA)

5ZE565 amphetamines

666KD9 MDMA

6SJ6SS MDMA

6SOTQX MDMA

6UPYUO 3,4-Methylenedioxymetamfetamine (MDMA)

7BXXXX MDMA

7V7ZMZ MDMA

8H6FT6 MDMA

8Q9HHM 3,4-Methylenedioxymetamfetamine (MDMA)

8T20G0 MDMA

90YC0Z MDMA

9NNWNO MDMA

9NQ999 MDMA

9P9B97 MDMA

APEFDF MDMA

AQAYT9 MDMA

AXDW2N 3,4-Methylenedioxymetamfetamine (MDMA)

B3EBPD 3,4-Methylenedioxy-metamfetamine

BIDPSO 3,4-methelynedioxy-metamfetamine(MDMA)

BOCUHG 3,4-Methylenedioxymetamfetamine (MDMA)

CAAEEE MDMA

DD6DWV MDMA

DEEJ5E MDMA

DMUL5S MDMA

DZYOGL Anfetamine

E666OG MDMA

EENDPO MDMA

GGCGG3 MDMA

GRIPEY Метамфетамин

GTNYPU THC, MDMA

GVGEP9 morphin

H8PYU5 MDMA

HCHYZY MDMA



Page 54 of 62

ICE 2020/2-BS


HHT9JH MDMA

HJCDJ2 3,4-Methylenedioxymetamfetamine (MDMA)

J0E7UI 3,4-methylenedioxymethamphetamine

JFDHCS 3,4- Methylenedioxy-methamfetamine(MDMA)

JMIFJG 3,4-Methylenedioxymetamfetamine (MDMA)

JMJLE1 Methylenedioxymethamphetamine

JOXEMT MDMA

JW3GXI MDMA

LAAAAA MDMA

LCXPWI 3,4-Methylendioxymetamfetamine (MDMA)

LGNUVH MDMA

LHZ8CT MDMA

LPN77A MDMA

MCZMMA MDMA

MFPKCL 3,4-Methylenedioxymetamfetamine (MDMA)

O2A2BN Mephedrone

O66Z5F Amfetamine grups

PDDDDD MDMA

PJ6NX9 3,4-Methylenedioxymetamfetamine (MDMA)

PPQ4MN MDMA

Q33R30 3,4-Methylenedioxymetamfetamine (MDMA)

QBVFBW MDMA (N-Methyl-3,4-methylenedioxyamphetamine)

QDFCD8 MDMA

REBSFB 3,4-Methylenedioxymetamfetamine (MDMA)

RMYQAR MDMA

SW25NX MDMA

T7ZWMT MDMA

T90OIT 3,4- Methylenedioxymetamfetamine (MDMA)

TCP07X 3,4-Methylenedioxymetamfetamine (MDMA)

U4DAAJ 3,4-Methylenedioxymetamfetamine (MDMA)

UOKKUT 3,4-Methylenedioxymetamfetamine (MDMA)

VLNX9X MDMA

VUASIY MDMA

W8VSHC MDMA

X2CTXX MDMA

XEHBYJ MDMA

Y2QOYO MDMA

YYXEXU 3,4-Methylenedioxymetamfetamine (MDMA)

ZQFW61 MDMA



Page 55 of 62

ICE 2020/2-BS


Code 3,4-Methylenedioxymetamfetamine (MDMA)

0R3CHB + -

4GKVKL + In the urine sample analyzed was detected and confirmed the presence of MDMA.

55O3RU - On TLC & GC-MS examination, sample was found to contain Caffeine and Opiates

5CHXK3 + 3,4-Methylenedioxymetamfetamine (MDMA) was detected in sample BS-4

5ZE565 + MDMA

666KD9 + Specimen 2020/2/BS-4 is positive for drug MDMA

6SJ6SS +

6SOTQX + Consistent with the use of MDMA

6UPYUO + SAMPLE 2020/2/BS-4 FOUND TO CONTAIN 3,4-Methylenedioxymetamfetamine (MDMA)

7BXXXX + Prior MDMA use

7V7ZMZ +

8H6FT6 + Use of Extasy.

8Q9HHM + Presence of 3,4-Methylenedioxymetamfetamine (MDMA) in the sample 2020/2/BS-4. N.B: The analysis must be confirmed by a chromatographic method to identify and quantify the found substance.

8T20G0 +

8V4YGY +

90YC0Z + this person consumed MDMA

9NNWNO +

9NQ999 + In the sample analyzed MDMA was found.

9P9B97 + MDMA was detected in sample 2020/2/BS-4

A65OOQ +



Page 56 of 62

ICE 2020/2-BS


AN3H29 -

APEFDF + Presence of MDMA

AQAYT9 + Amphetamine group was determined as a positive indicator in screening analysis which was then confirmed quantitively that the sample contained MDMA

AXDW2N + 3,4-Methylenedioxymetamfetamine (MDMA) was identified by GC/MS analysis

B3EBPD + MDMA was found

BIDPSO + 3,4-methylenedioxymetamfetamine is a stimulant and a hallucinogen.

BOCUHG + Positive to 3,4-Methylenedioxymetamfetamine (MDMA)

CAAEEE + QUETIAPINE, CAFFEINE

DD6DWV + positive

DEEJ5E + MDMA user

DMUL5S +

DZYOGL - A solid phase extraction for anfetamines was performed and confirmed by a specific analysis method in GC/MS

E666OG + MDMA

EENDPO + MDMA was detected in BS-4 Sample.

EENW2Z - None of the substances refered to in the list

FCUPDY ANP

GGCGG3 + recent intake of MDMA, noticeable the absence of MDA, its metabolite. No information on the conditions of the subject at the time of sample collection.

GRIPEY -

GTNYPU +

GVGEP9 -

H8PYU5 + It indicates the intake of MDMA.



Page 57 of 62

ICE 2020/2-BS


HCHYZY + La MDMA, aussi appelée ecstasy, est une drogue illicite que l’on trouve en France principalement sous forme de pilules. C’est un entactogène amphétamines utilisées dans les fêtes.

HHT9JH + in the urine MDMA and caffeine were identified

HJCDJ2 + screening with rapid test kit and quantitation by LC-MS

J0E7UI + we found 3,4-methylenedioxymethamphetamine as narcotic substance

JFDHCS + The drug that has been found is 3,4- Methylenedioxy-methamfetamine(MDMA). It belongs to the class of AMPHETAMINE.

JMIFJG +

JMJLE1 + Methylenedioxmethamphetamine was detected in 2020/2/BS-4

JOXEMT + MDMA WAS IDENTIFIED IN THE SAMPLE 4

JW3GXI + MDMA was detected in 2020/2/BS-4 sample.

KWLGGO +

LAAAAA + la présence de la MDMA dans BS4 a été identifiée par 161 technic

LCXPWI +

LGNUVH + Amphetamine-type stimulant drug is detected in sample number four, by both GC/MS and EIA, and confirmed as MDMA by LC-MS/MS

LHZ8CT + Positive for MDMA

LPN77A + MDMA 1373 ng/ml

MCZMMA +

MFPKCL +

O2A2BN -

O66Z5F + 3,4-Methylenedioxymetamfetamine (MDMA)

PDDDDD + 3,4-Methylenedioxymetamfetamine detected

PJ6NX9 + 3,4-Methylenedioxymetamfetamine (MDMA) is as listed in the First Schedule of Dangerous Drugs Act 1952.



Page 58 of 62

ICE 2020/2-BS


PPQ4MN +

Q33R30 + 3,4-Methylenedioxymetamfetamine (MDMA) was detected in Sample 2020/2/BS-4.

QBVFBW +

QDFCD8 +

QMPZYH +

REBSFB + Test sample 2020/2/BS-4 was found to contain controlled drugs for 3,4- Methylenedioxymetamfetamine (MDMA), therefore Positive for the Screening and Confirmatory analyses with concentration value of 765.78 ng/mL.

RMYQAR + MDMA Detected > 0.5mg/L

SW25NX + MDMA is a derivative of Amphetamine

T7ZWMT + we also found traces of caffeine and theobromine

T90OIT + In sample BS-4 the drug 3,4- methylenedioxymetamfetamine (MDMA) was detected.

TCP07X +

U4DAAJ +

UOKKUT +

V4VTFQ +

VLNX9X +

VUASIY +

W8VSHC +

X2CTXX + 2020/2/BS-4 was containing MDMA

XEHBYJ + Sample 2020/2/BS-4 contain MDMA

Y2QOYO + Analytical Adverse Finding for MDMA

YYXEXU + 3,4-Methylenedioxymetamfetamine (MDMA)

ZQFW61 + MDMA detected



Page 59 of 62

ICE 2020/2-BS



Code 100 110 142 150 160 161 170 180 190 230 231 210

0R3CHB I SI

4GKVKL SI SI I

55O3RU SI I

5CHXK3 S SI SI

5ZE565 I SI

666KD9 S I I I

6SJ6SS S I SI

6SOTQX I SI

6UPYUO SI

7BXXXX SI SI

7V7ZMZ S I

8H6FT6 I I SI


8T20G0 S I I

8V4YGY S I I

90YC0Z S I I

9NNWNO I

9NQ999 S I

9P9B97 I

A65OOQ S I I

AN3H29 I

APEFDF S S SI I

AQAYT9 S I

AXDW2N S I

B3EBPD I I S COBAS

BIDPSO I I

BOCUHG S SI

CAAEEE SI I


DEEJ5E SI

DMUL5S S I I




Page 60 of 62

ICE 2020/2-BS

Code 100 110 142 150 160 161 170 180 190 230 231 210

DZYOGL S I

E666OG S I SI

EENDPO I

EENW2Z S I

FCUPDY S I

GGCGG3 S I

GRIPEY S I

GTNYPU I

GVGEP9 S I

H8PYU5 S I SI

HCHYZY S I I

HHT9JH SI

HJCDJ2 S I I

J0E7UI S I


JMIFJG S I

JMJLE1 SI SI

JOXEMT SI

JW3GXI S I I I

KWLGGO S I I

LAAAAA S I SI

LCXPWI I I

LGNUVH S I I

LHZ8CT S I I

LPN77A I SI I



O2A2BN SI LC TOFMS


PDDDDD I

PJ6NX9 I

PPQ4MN I

Q33R30 SI

QBVFBW S I I

QDFCD8 SI

QMPZYH S I I

REBSFB I S DTK



Page 61 of 62

ICE 2020/2-BS

Code 100 110 142 150 160 161 170 180 190 230 231 210

RMYQAR S I I

SW25NX S I

T7ZWMT SI I

T90OIT SI SI

TCP07X I


UOKKUT S I


VLNX9X S I SI

VUASIY S I

W8VSHC S I

X2CTXX S I


Y2QOYO SI SI

YYXEXU S I SI

ZQFW61 SI



Page 62 of 62

ICE 2020/2-BS

THIS PAGE IS INTENTIONALLY BLANK

Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria

Tel. : (+43-1) 26060-0, Fax : (+43-1) 26060-5866, www.unodc.org

INTERNATIONAL COLLABORATIVE EXERCISES (ICE)

Documents

Transcript of INTERNATIONAL COLLABORATIVE EXERCISES (ICE)